Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...

Shares of Geron (NASDAQ:GERN) plunged 30% Wednesday after management reportedly indicated on the company's Q4 earnings call ...

Geron stock is seeing a dramatic pullback following the company's fourth-quarter report. Geron's earnings in Q4 fell short of Wall Street's expectations, and management had worrying guidance for ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected. The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Rytelo's market share in second-line LR-MDS is ...

Geron (GERN) Corporation announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.